Bibhuti B Das1, Chantale Lacelle2, Song Zhang3, Ang Gao3, David Fixler1. 1. Division of Pediatric Cardiology, UT Southwestern Medical Center, Dallas, TX. 2. Department of Pathology, UT Southwestern Medical Center, Dallas, TX. 3. Department of Clinical Science Research, UT Southwestern Medical Center, Dallas, TX.
Abstract
BACKGROUND: We hypothesized C1q binding de novo donor-specific antibody (DSA) after heart transplant (HT) is a higher risk for development of coronary artery vasculopathy (CAV) in children. METHODS: A retrospective analysis of 127 pediatric HT recipients transplanted between January 2005 and December 2014 was used to determine complement (C1q)-binding de novo DSA on the outcomes of HT and the ability of the C1q assay to predict CAV development. RESULTS: Of 127 patients, 59 (46.4%) developed de novo DSA, 37 of those had C1q+ DSA. There was no difference in baseline characteristics except patients who developed C1q+ DSA more often received a donor heart from a female compared with C1q- DSA group (P = 0.034). The DSA median fluorescent intensity (MFI) value of 7000 or greater had 80% sensitivity and 80% specificity (C statistics 0.89, P <0.05) for predicting positive C1q binding. Multivariate analyses identified C1q binding DSA as an independent risk for CAV with a hazard ratio (HR) of 3.25 (95% confidence interval [CI], 1.33-7.93; P = 0.0095). In multivariable Cox proportional hazard models, the covariates associated with graft loss included: C1q+ DSA (HR, 3.2; 95% CI, 1.34-7.86; P < 0.009), pre-HT renal insufficiency (HR, 11.3; 95% CI, 3.71-34.29; P < 0.0001), and pre-HT ventilator support (HR, 3.3; 95% CI, 1.39-7.81; P = 0.007). CONCLUSIONS: The DSA strength in MFI correlates with positive C1q-binding activity and hence functional capabilities of DSA. Close monitoring of DSA strength in MFI and function (C1q assay) may be useful for identifying pediatric HT recipient at risk for development of CAV.
BACKGROUND: We hypothesized C1q binding de novo donor-specific antibody (DSA) after heart transplant (HT) is a higher risk for development of coronary artery vasculopathy (CAV) in children. METHODS: A retrospective analysis of 127 pediatric HT recipients transplanted between January 2005 and December 2014 was used to determine complement (C1q)-binding de novo DSA on the outcomes of HT and the ability of the C1q assay to predict CAV development. RESULTS: Of 127 patients, 59 (46.4%) developed de novo DSA, 37 of those had C1q+ DSA. There was no difference in baseline characteristics except patients who developed C1q+ DSA more often received a donor heart from a female compared with C1q- DSA group (P = 0.034). The DSA median fluorescent intensity (MFI) value of 7000 or greater had 80% sensitivity and 80% specificity (C statistics 0.89, P <0.05) for predicting positive C1q binding. Multivariate analyses identified C1q binding DSA as an independent risk for CAV with a hazard ratio (HR) of 3.25 (95% confidence interval [CI], 1.33-7.93; P = 0.0095). In multivariable Cox proportional hazard models, the covariates associated with graft loss included: C1q+ DSA (HR, 3.2; 95% CI, 1.34-7.86; P < 0.009), pre-HT renal insufficiency (HR, 11.3; 95% CI, 3.71-34.29; P < 0.0001), and pre-HT ventilator support (HR, 3.3; 95% CI, 1.39-7.81; P = 0.007). CONCLUSIONS: The DSA strength in MFI correlates with positive C1q-binding activity and hence functional capabilities of DSA. Close monitoring of DSA strength in MFI and function (C1q assay) may be useful for identifying pediatric HT recipient at risk for development of CAV.
Authors: Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham Journal: J Heart Lung Transplant Date: 2005-06-20 Impact factor: 10.247
Authors: Eric K Ho; George Vlad; Elena Rodica Vasilescu; Ludwika de la Torre; Adriana I Colovai; Elizabeth Burke; Mario Deng; Joseph Schwartz; Charles Marboe; Donna Mancini; Gerhard Opelz; Nicole Suciu-Foca Journal: Hum Immunol Date: 2010-11-10 Impact factor: 2.850
Authors: A R Tambur; N D Herrera; K M K Haarberg; M F Cusick; R A Gordon; J R Leventhal; J J Friedewald; D Glotz Journal: Am J Transplant Date: 2015-04-30 Impact factor: 8.086
Authors: Adriana Zeevi; John Lunz; Brian Feingold; Michael Shullo; Christian Bermudez; Jeffery Teuteberg; Steven Webber Journal: J Heart Lung Transplant Date: 2012-11-09 Impact factor: 10.247
Authors: J D Smith; N R Banner; I M Hamour; M Ozawa; A Goh; D Robinson; P I Terasaki; M L Rose Journal: Am J Transplant Date: 2011-01-10 Impact factor: 8.086
Authors: Hidetoshi Tsuda; Nina Dvorina; Karen S Keslar; Jessica Nevarez-Mejia; Nicole M Valenzuela; Elaine F Reed; Robert L Fairchild; William M Baldwin Journal: Am J Pathol Date: 2022-04-29 Impact factor: 5.770
Authors: Antoine Bouquegneau; Charlotte Loheac; Olivier Aubert; Yassine Bouatou; Denis Viglietti; Jean-Philippe Empana; Camilo Ulloa; Mohammad Hassan Murad; Christophe Legendre; Denis Glotz; Annette M Jackson; Adriana Zeevi; Stephan Schaub; Jean-Luc Taupin; Elaine F Reed; John J Friedewald; Dolly B Tyan; Caner Süsal; Ron Shapiro; E Steve Woodle; Luis G Hidalgo; Jacqueline O'Leary; Robert A Montgomery; Jon Kobashigawa; Xavier Jouven; Patricia Jabre; Carmen Lefaucheur; Alexandre Loupy Journal: PLoS Med Date: 2018-05-25 Impact factor: 11.069
Authors: Bibhuti B Das; Bhupesh K Prusty; Jianli Niu; Meei-Li Huang; Haiying Zhu; Eva Eliassen; Jane M Kuypers; Keith R Jerome Journal: Ann Pediatr Cardiol Date: 2020-09-01
Authors: Katarzyna Zielińska; Leszek Kukulski; Marta Wróbel; Piotr Przybyłowski; Dominika Rokicka; Krzysztof Strojek Journal: Ann Transplant Date: 2022-02-15 Impact factor: 1.530